Addex Therapeutics Ltd ADR (ADXN) Stock Price, Quote & News

Company Profile

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate re...

Industry: Biotechnology

Sector: Healthcare

Phone: 41 22 884 1555

Fax: 41 22 884 1556

Website: www.addextherapeutics.com

Address:

Chemin des Mines, 9, Geneva, Switzerland

Alflong1 Nov. 13 at 4:29 PM

$ADXN ok we got movement!!! Let’s go!!!

0 · Reply

PIGMONKEYTV Nov. 12 at 3:31 PM

$ADXN finding the quiet places, buying, and waiting.. hasnt failed yet..

0 · Reply

Alflong1 Nov. 12 at 2:41 PM

$ADXN 3rd straight day of minimal volume. So frustrating!!

0 · Reply

Alflong1 Nov. 10 at 6:04 PM

$ADXN no volume at all!! Delisting!

1 · Reply

BenKaitz Nov. 5 at 6:14 PM

$ADXN seven potential partnership announcements and three expected positive catalysts in the next couple months:

1 · Reply

BenKaitz Nov. 5 at 6:13 PM

$ADXN

0 · Reply

Eliza1 Nov. 3 at 9:04 PM

$ADXN wow. I would hate to be short this stock right now. Get ready for a big move up this week. JMHO

0 · Reply

Eliza1 Oct. 31 at 9:55 PM

$ADXN I repeat the below. We are getting closer to that point. I prefer a PR and a 7 am opening of $75+... Good Luck!

0 · Reply

Eliza1 Oct. 29 at 1:20 PM

$ADXN stocks have been flying on similar news. If you read the article-the number of shares outstanding does not change. So, NO MORE SHARES.

1 · Reply

flybyme Oct. 29 at 8:53 AM

$ADXN so more Shares https://www.addextherapeutics.com/en/investors/press-releases/addex-increases-issued-share-capital-create-treasury-shares4/

0 · Reply

Addex Therapeutics Ltd (ADXN) Q2 2025 Earnings Call Transcript

Sep 30, 2025, 1:00 AM EDT - 6 weeks ago

Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update

Sep 26, 2025, 1:00 AM EDT - 7 weeks ago

Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025

Sep 23, 2025, 1:00 AM EDT - 7 weeks ago

Addex Appoints Bank of New York Mellon as Depositary Bank

Jun 30, 2025, 1:00 AM EDT - 4 months ago

Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs

Jun 30, 2025, 1:00 AM EDT - 4 months ago

Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders

Jun 25, 2025, 1:00 AM EDT - 5 months ago

Addex Shareholders Approve All Resolutions at Annual General Meeting

Jun 19, 2025, 1:00 AM EDT - 5 months ago

Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update

Jun 18, 2025, 1:00 AM EDT - 5 months ago

Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025

Jun 6, 2025, 1:00 AM EDT - 5 months ago

Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models

Jun 3, 2025, 1:00 AM EDT - 5 months ago

Addex Convenes Annual General Meeting 2025

May 12, 2025, 1:00 AM EDT - 6 months ago

Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies

Apr 30, 2025, 1:00 AM EDT - 7 months ago

Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery

Apr 25, 2025, 4:40 PM EDT - 7 months ago

Addex Therapeutics Ltd (ADXN) Q4 2024 Earnings Call Transcript

Apr 25, 2025, 1:00 AM EDT - 7 months ago

Addex Reports Full Year 2024 Financial Results and Provides Corporate Update

Apr 17, 2025, 1:00 AM EDT - 7 months ago

Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149

Jan 8, 2025, 1:00 AM EST - 11 months ago

Addex to Present at the 2025 Swiss Equities Baader Conference

Nov 22, 2024, 11:11 AM EST - 1 year ago

Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Transcript

Nov 22, 2024, 1:00 AM EST - 1 year ago

Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 11, 2024, 1:00 AM EST - 1 year ago

Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024

Sep 30, 2024, 12:04 PM EDT - 1 year ago

Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript

Sep 30, 2024, 1:00 AM EDT - 1 year ago

Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update

Sep 19, 2024, 1:00 AM EDT - 1 year ago

Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit

Sep 4, 2024, 1:00 AM EDT - 1 year ago

Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 27, 2024, 12:03 PM EDT - 1 year ago

Crude Oil Dips; Addex Therapeutics Shares Spike Higher

Aug 27, 2024, 10:47 AM EDT - 1 year ago

Why Addex Therapeutics stock skyrocketed 70% on Tuesday

Aug 27, 2024, 1:00 AM EDT - 1 year ago

Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration

Jul 22, 2024, 1:00 AM EDT - 1 year ago

Addex's Partner Discontinues ADX71149 development in Epilepsy

Jul 15, 2024, 1:00 AM EDT - 1 year ago

Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)

Jul 12, 2024, 1:00 AM EDT - 1 year ago

Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)

Jun 6, 2024, 12:50 PM EDT - 1 year ago

Addex Therapeutics Ltd (ADXN) Q1 2024 Earnings Call Transcript

Jun 6, 2024, 1:00 AM EDT - 1 year ago

Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update

Jun 5, 2024, 1:00 AM EDT - 1 year ago

Addex Convenes Annual General Meeting 2024

May 31, 2024, 1:00 AM EDT - 1 year ago

Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024

May 8, 2024, 1:00 AM EDT - 1 year ago

Addex to Present at Bio€quity Europe 2024

Apr 29, 2024, 1:00 AM EDT - 1 year ago

Addex Provides Update on ADX71149 Phase 2 Epilepsy Study

Apr 19, 2024, 1:00 AM EDT - 1 year ago

Addex to Present at the Swiss Biotech Day 2024

Apr 18, 2024, 1:46 PM EDT - 1 year ago

Addex Therapeutics Ltd (ADXN) Q4 2023 Earnings Call Transcript

Apr 18, 2024, 1:00 AM EDT - 1 year ago

Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

Apr 11, 2024, 1:00 AM EDT - 1 year ago

Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024

Apr 3, 2024, 1:00 AM EDT - 1 year ago

Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders

Mar 14, 2024, 2:00 AM EDT - 1 year ago

Addex to Present at the Bio-Europe Spring 2024 Conference

Jan 31, 2024, 1:00 AM EST - 1 year ago

Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.

Jan 9, 2024, 1:00 AM EST - 2 years ago

Addex to Present at the Swiss Equities Baader Conference

Jan 5, 2024, 1:30 AM EST - 2 years ago

Addex to Present at Biotech Showcase™ 2024

Dec 20, 2023, 1:00 AM EST - 2 years ago

Addex Shareholders Approve All Resolutions at Extraordinary General Meeting

Dec 14, 2023, 1:00 AM EST - 2 years ago

Addex Creates Treasury Shares

Nov 29, 2023, 1:41 PM EST - 2 years ago

Addex Therapeutics Ltd (ADXN) Q3 2023 Earnings Call Transcript

Nov 29, 2023, 1:00 AM EST - 2 years ago

Addex Reports Q3 2023 Financial Results and Provides Corporate Update

Nov 28, 2023, 1:00 AM EST - 2 years ago

Addex Convenes Extraordinary General Meeting

Alflong1 Nov. 13 at 4:29 PM

$ADXN ok we got movement!!! Let’s go!!!

0 · Reply

PIGMONKEYTV Nov. 12 at 3:31 PM

$ADXN finding the quiet places, buying, and waiting.. hasnt failed yet..

0 · Reply

Alflong1 Nov. 12 at 2:41 PM

$ADXN 3rd straight day of minimal volume. So frustrating!!

0 · Reply

Alflong1 Nov. 10 at 6:04 PM

$ADXN no volume at all!! Delisting!

1 · Reply

BenKaitz Nov. 5 at 6:14 PM

$ADXN seven potential partnership announcements and three expected positive catalysts in the next couple months:

1 · Reply

BenKaitz Nov. 5 at 6:13 PM

$ADXN

0 · Reply

Eliza1 Nov. 3 at 9:04 PM

$ADXN wow. I would hate to be short this stock right now. Get ready for a big move up this week. JMHO

0 · Reply

Eliza1 Oct. 31 at 9:55 PM

$ADXN I repeat the below. We are getting closer to that point. I prefer a PR and a 7 am opening of $75+... Good Luck!

0 · Reply

Eliza1 Oct. 29 at 1:20 PM

$ADXN stocks have been flying on similar news. If you read the article-the number of shares outstanding does not change. So, NO MORE SHARES.

1 · Reply

flybyme Oct. 29 at 8:53 AM

$ADXN so more Shares https://www.addextherapeutics.com/en/investors/press-releases/addex-increases-issued-share-capital-create-treasury-shares4/

0 · Reply

Eliza1 Oct. 28 at 7:21 PM

$ADXN this is a $75 stock with the current market valuation. JMHO. It will happen with the next positive PR. The same with $WLDS

1 · Reply

Eliza1 Oct. 27 at 6:35 PM

$ADXN great article but not widely distributed. A PR from the company concerning any of the major positive points in the article would get this stock continued attention-anyone still short here is crazy with this market continuing to reach new highs.

0 · Reply

BioTechHealthX Oct. 26 at 7:15 AM

$ADXN Addex regains global drug rights and targets multi-billion-dollar markets in neurology. Early investors are watching closely. https://biotechhealthx.com/biotech-info/addex-therapeutics-adxn-is-on-the-brink-of-a-breakout/

0 · Reply

NinjaaRai Oct. 24 at 8:18 PM

$ADXN $FUSE $QLGN $WGRX

0 · Reply

SpartanVI Oct. 24 at 8:16 PM

$ADXN $FUSE $QLGN $WGRX Fuse looks ready for ah

0 · Reply

SpartanVI Oct. 24 at 7:26 PM

$ADXN $FUSE $QLGN $WGRX Fuse Oversold here Potential reversal

0 · Reply

Eliza1 Oct. 24 at 5:00 PM

$ADXN can we just fill the $35 gap already?Another huge one at around $75-$80 when the market was much lower.

0 · Reply

Aaronwasinger Oct. 24 at 8:32 AM

$ADXN $FUSE $QLGN $WGRX

0 · Reply

SpartanVI Oct. 24 at 8:31 AM

$FUSE '' Charles Cassel hedge manager : predicts 200mil valuation potential // next Q revenue to reveal after it gets uplisted *makes the most sense* // '' $QLGN $ADXN $WGRX

0 · Reply

Manor007 Oct. 23 at 8:19 PM

$ADXN load...load...on fire

0 · Reply

Manor007 Oct. 23 at 8:11 PM

$ADXN mark my word....

0 · Reply

Manor007 Oct. 23 at 8:01 PM

$ADXN going up

1 · Reply

Market Cap	9.11M
Revenue (ttm)	460,000.00
Net Income (ttm)	8.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	1,741.30%
Debt to Equity Ratio	0.00

Volume	3,100
Avg Vol	36,248
Day's Range	N/A - N/A
Shares Out	1.06M
Stochastic %K	0%
Beta	1.37
Analysts	Strong Buy
Price Target	$30.00